Literature DB >> 16386668

Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.

Clyde W Yancy1, Margarita Lopatin, Lynne Warner Stevenson, Teresa De Marco, Gregg C Fonarow.   

Abstract

UNLABELLED: Approximately 50% of patients hospitalized for heart failure have preserved systolic function. These patients are more likely to be older, women, and hypertensive. Their duration of hospitalization is similar to that of heart failure patients with systolic dysfunction, but their in-hospital mortality risk is lower. This mortality risk is increased in the setting of renal insufficiency, and the two most important risk predictors are elevated blood urea nitrogen and systolic blood pressure < or = 125 mm Hg. Medical treatment strategies for patients with preserved systolic function are inconsistent and reflect the need for efficacious evidence-based treatment regimens.
OBJECTIVES: The aims of this analysis were to describe the clinical characteristics, management, and outcomes of patients hospitalized for acute decompensated heart failure (HF) with preserved systolic function (PSF).
BACKGROUND: Clinically meaningful characteristics of these patients have not been fully studied in a large database.
METHODS: Data from >100,000 hospitalizations from the Acute Decompensated Heart Failure National Registry (ADHERE) database were analyzed.
RESULTS: Heart failure with PSF was present in 50.4% of patients with in-hospital assessment of left ventricular function. When compared with patients with systolic dysfunction, patients with PSF were more likely to be older, women, and hypertensive and less likely to have had a prior myocardial infarction or be receiving an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. In-hospital mortality was lower in patients with PSF compared with patients with systolic dysfunction (2.8% vs. 3.9%; adjusted odds ratio [OR]: 0.86; p = 0.005), but duration of intensive care unit stay and total hospital length of stay were similar. Serum creatinine >2 mg/dl was associated with increased in-hospital mortality in both systolic function groups (PSF: 4.8%; systolic dysfunction: 8.4%; p < 0.0001), and the most powerful predictors of in-hospital mortality in both groups were blood urea nitrogen >37 mg/dl (OR: 2.53; 95% confidence interval [CI]: 2.22 to 2.87) and systolic blood pressure < or =125 mm Hg (OR: 2.58; 95% CI: 2.33 to 2.86).
CONCLUSIONS: Heart failure with PSF is common and is characterized by a unique patient profile. Event rates are worrisome and reflect a need for more effective management strategies.

Entities:  

Mesh:

Year:  2005        PMID: 16386668     DOI: 10.1016/j.jacc.2005.09.022

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  281 in total

1.  A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.

Authors:  Mihai Gheorghiade; Peter S Pang; Andrew P Ambrosy; Gloria Lan; Philip Schmidt; Gerasimos Filippatos; Marvin Konstam; Karl Swedberg; Thomas Cook; Brian Traver; Aldo Maggioni; John Burnett; Liliana Grinfeld; James Udelson; Faiez Zannad
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Authors:  Sameer Ather; Wenyaw Chan; Biykem Bozkurt; David Aguilar; Kumudha Ramasubbu; Amit A Zachariah; Xander H T Wehrens; Anita Deswal
Journal:  J Am Coll Cardiol       Date:  2012-03-13       Impact factor: 24.094

3.  Congestion is the driving force behind heart failure.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2012-09

4.  In-hospital management of heart failure: in 10 years we have improved, but not enough.

Authors:  Sonia Ferretto; Chiara Dalla Valle; Sonia Cukon Buttignoni; Luca Brugnaro; Giovanni Maria Boffa
Journal:  Intern Emerg Med       Date:  2010-12-09       Impact factor: 3.397

5.  Trends in prevalence of comorbidities in heart failure clinical trials.

Authors:  Muhammad Shahzeb Khan; Ayman Samman Tahhan; Muthiah Vaduganathan; Stephen J Greene; Alaaeddin Alrohaibani; Stefan D Anker; Orly Vardeny; Gregg C Fonarow; Javed Butler
Journal:  Eur J Heart Fail       Date:  2020-04-15       Impact factor: 15.534

6.  Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).

Authors:  Robert J Goldberg; Jerry H Gurwitz; Jane S Saczynski; Grace Hsu; David D McManus; David J Magid; David H Smith; Alan S Go
Journal:  Am J Cardiol       Date:  2013-02-01       Impact factor: 2.778

7.  Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.

Authors:  Mostafa El-Refai; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear
Journal:  J Card Fail       Date:  2013-02       Impact factor: 5.712

8.  Prognostic value of increased carbohydrate antigen in patients with heart failure.

Authors:  Ana B Méndez; Jordi Ordoñez-Llanos; Andreu Ferrero; Mariana Noguero; Teresa Mir; Josefina Mora; Antoni Bayes-Genis; Sònia Mirabet; Juan Cinca; Eulàlia Roig
Journal:  World J Cardiol       Date:  2014-04-26

9.  Impact of Ethnicity, Sex, and Socio-Economic Status on the Risk for Heart Failure Readmission: The Importance of Context.

Authors:  Sonia G Ponce; Jeffrey Norris; Diane Dodendorf; Melissa Martinez; Bart Cox; Warren Laskey
Journal:  Ethn Dis       Date:  2018-04-26       Impact factor: 1.847

10.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.